Both stocks run through our valuation models. Here is how Cyclopharm (CYC) and McKesson (MCK) compare, as of Aug 10, 2026.
As of Aug 10, 2026, Fair Value Calculator sees McKesson as the less overvalued of the two: Cyclopharm trades at A$0.57 versus a fair value of A$0.08 (-86%), while McKesson trades at $870 versus $819 (-6%).
Cyclopharm
CYC.AU · AUD · Health Care
-86%
upside to fair value
overvalued
PriceA$0.57
Fair ValueA$0.08
Quality34/100
McKesson
MCK · USD · Health Care
-6%
upside to fair value
fairly valued
Price$870
Fair Value$819
Quality66/100
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
CyclopharmMcKesson
Valuation
—P/E (TTM)21.0×
1.65×P/S (TTM)0.23×
1.97×P/B—
—EV/EBITDA13.9×
—PEG1.57×
—Dividend yield0.4%
—Dividend per share$3.17
Profitability
-53%Net margin1%
-52%Operating margin2%
-49%Return on equity—
-20%Return on assets5%
Growth
11%Revenue growth (YoY)6%
11.7%Avg. growth/yr (3Y)13.4%
17.1%Avg. growth/yr (5Y)11.1%
Balance & size
$53MMarket cap$94B
expensiveGrowth qualityhealthy
McKesson leads: 2 to 5 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
Cyclopharmof which business quality 34 · market factors 19McKessonof which business quality 65 · market factors 63
ProfitabilityMargins and returns on capital today
10
49
Quality GrowthAre margins and returns improving?
43
65
CashflowEarnings quality: real cash, not paper profit
InvestmentDisciplined investing over empire-building
92
76
Low VolatilityCalm price path (market factor)
48
83
MomentumPrice trend over the last 3–12 months (market factor)
8
51
52W MomentumDistance to the 52-week high (market factor)
7
62
Net IssuanceBuybacks instead of dilution
14
100
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
Cyclopharm
Asset-BasedA$0.14
1 of 1 models see the stock below the current price.
McKesson
DCF Models$955
Earnings-Based$444
Dividend Discount$57.26
Multiples$848
Growth DCF$922
Economic Profit$497
Growth Earnings$708
13 of 23 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Cyclopharm
Bear A$0.05Fair Value A$0.08Bull A$0.09
A$0.57 = current price (white tick)
McKesson
Bear $605Fair Value $819Bull $1,034
$870 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Free, no sign-up
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Cyclopharm · Health Care
Quality score34 · bottom 25%
Fair value upside-86% · bottom 25%
McKesson · Health Care
Quality score66 · Top 25%
Fair value upside-6% · above median
Bottom line
As of Aug 10, 2026, Fair Value Calculator sees McKesson as the less overvalued of the two: Cyclopharm trades at A$0.57 versus a fair value of A$0.08 (-86%), while McKesson trades at $870 versus $819 (-6%).
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
